Searchable abstracts of presentations at key conferences in endocrinology

ea0020s16.1 | Neuroendocrine tumors | ECE2009

Novel approaches in the treatment of NET

Oberg Kjell

Neuroendocrine tumors (NETs) constitute a rather heterogenous group of malignancies that are considered to be rare. However, resent data is indicating a significant increase in both incidence and prevalence over the last decades, with an overall incidence of 5/100 000/year and prevalence of 25/100 000/year.The treatment of NETs is based on the tumor biology (proliferation capacity and differentiation), tumor localisation and spread (TNM-staging). Surgery...

ea0014s17.2 | Somatostatin receptors in health and disease | ECE2007

Somatostatin receptors in neuroendocrine tumors

Oberg Kjell

A unique feature of neuroendocrine tumors is that they express peptide hormone receptors. All five subtypes of somatostatin receptors are expressed in neuroendocrine tumors with dominance for receptor type 2 (SST2). Stimulation of SST2 can not only inhibit hormone release from the tumor, but also tumor cell growth. Both SST2 and 3 are involved in apoptosis of neuroendocrine tumor cells. SST’s in intratumoral blood vessels might implicate a role of anti-angiogenesis of som...

ea0037ep1139 | Endocrine tumours | ECE2015

Neuroendocrine tumor European patient experience: results from the first global NET patient survey – a collaboration between the International Neuroendocrine Cancer Alliance and Novartis

Oberg Kjell , Leyden John , Goldstein Grace , Sissons Maia , Kolarova Teodora

Background: NETs are a rare heterogeneous group of malignancies, often with a delayed diagnosis. Although diagnosis of NETs is increasing (due in part to greater awareness), little has been published on the NET patient experience. We present data on the EU NET patient perspective.Methods: In 2014, 1928 NET patients from >12 countries, including EU (n=763: Belgium, Bulgaria, France, Germany, Norway, UK, other EU countries (not specified by re...

ea0070aep567 | Pituitary and Neuroendocrinology | ECE2020

Multigene liquid biopsy (NETest) is diagnostic of pancreatic and small bowel neuroendocrine tumours and correlates with imaging

Malczewska Anna , Witkowska Magdalena , Makulik Karolina , Bocian Agnes , Walter Agata , Wojcik-Giertuga Monika , Pilch-Kowalczyk Joanna , Zajecki Wojciech , Bodei Lisa , Oberg Kjell , Kos-Kudla Beata

Introduction: There is a substantial unmet clinical need for an accurate and effective blood biomarker for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Current monoanalyte biomarkers are ineffective. The NETest, a novel multianalyte signature, provides molecular information relevant to disease biology. We therefore evaluated, under real-world conditions, the clinical utility of the NETest as a liquid biopsy in GEP-NETs.Aim(s): Independently ...

ea0072p1 | (1) | UKINETS2020

Post-operative NETest scores detect residual NET disease and accurately predicts tumor recurrence in R0

Modlin Irvin , Kidd Mark , Oberg Kjell , Falconi Massimo , Luigi Filosso5 Pier , Frilling Andrea , Malczewska Anna , Salem Ronald , Toumpanakis Christos , Laskaratos Faidon-Marios , Partelli Stefano , Roffinella Matteo , Arx Claudia von , Kos-Kudla Beata , Bodei Lisa , Drozdov Ignat , Kitz Alexandra

Introduction: Surgery is the only cure for neuroendocrine tumor (NET) disease. R0 resection is critical for successful tumor resection. Early detection of residual disease is key for optimal management. Both imaging and current biomarkers have intrinsic limitations and are largely ineffective up to 3 months post-surgery. NETest, a multigene blood biomarker test, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scor...

ea0046p11 | (1) | UKINETS2016

Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews

Anthony Lowell , Horsch Dieter , Ervin Claire , Kulke Matthew H. , Pavel Marianne , Bergsland Emily , Caplin Martyn , Oberg Kjell , Warner Richard , Kunz Pamela , Metz David C. , Pasieka Janice , Pavlakis Nick , DiBenedetti Dana , Haydysch Emily , Yang Qi Melissa , Jackson Shanna , Arnold Karie , Law Linda , Lapuerta Pablo

Background: Telotristat etiprate (TE), an oral tryptophan hydroxylase inhibitor, is intended to treat carcinoid syndrome (CS) by reducing serotonin production. TE was evaluated in TELESTAR, a phase 3 study; the primary endpoint showed significant reductions in bowel movement (BM) frequency for 2 TE dosages + standard of care (SOC) vs. SOC. TELESTAR patients had CS inadequately controlled on somatostatin analog therapy with ≥4 BMs per day. They were interviewed about base...